About Biologic Medicines

At Juno, our goal is twofold: increase patient access to high quality, lifesaving medicines and increase value within the Australian healthcare system.

Biosimilars and interchangeable biologic products present an opportunity to patients, healthcare professionals and the government, by providing increased patient access to therapies, whilst helping maintain the long-term viability and financial sustainability of the Australian and New Zealand healthcare systems.

We believe that we have the right expertise and strategies to effectively partner with biologic developers whose brands are reaching their patent expiry, plus biosimilar developers with plans to launch in Australia and New Zealand.



Switching is a decision initiated by clinicians, to exchange one medicine for another medicine with the same therapeutic intent25, a practice which is considered safe for biological medicines25,26. Over a decade of experience in Europe, from thousands of patients, consistently shows that switching between new versions of the originator biologic, or between a reference biologic and a biosimilar, does not affect safety, efficacy or immunogenicity19.

European Public Assessment Reports (EPARs) available on the European Medicines Agency (EMA) website, offer substantial evidence for the safety of a switch, and can be viewed here.